Phage therapy as a glimmer of hope in the fight against the recurrence or emergence of surgical site bacterial infections.
Antibiotic resistance
Biofilms
Phages
Surgery
Surgical site infections
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
19
09
2023
accepted:
05
01
2024
pubmed:
3
2
2024
medline:
3
2
2024
entrez:
2
2
2024
Statut:
ppublish
Résumé
Over the last decade, surgery rates have risen alarmingly, and surgical-site infections are expanding these concerns. In spite of advances in infection control practices, surgical infections continue to be a significant cause of death, prolonged hospitalization, and morbidity. As well as the presence of bacterial infections and their antibiotic resistance, biofilm formation is one of the challenges in the treatment of surgical wounds. This review article was based on published studies on inpatients and laboratory animals receiving phage therapy for surgical wounds, phage therapy for tissue and bone infections treated with surgery to prevent recurrence, antibiotic-resistant wound infections treated with phage therapy, and biofilm-involved surgical wounds treated with phage therapy which were searched without date restrictions. It has been shown in this review article that phage therapy can be used to treat surgical-site infections in patients and animals, eliminate biofilms at the surgical site, prevent infection recurrence in wounds that have been operated on, and eradicate antibiotic-resistant infections in surgical wounds, including multi-drug resistance (MDR), extensively drug resistance (XDR), and pan-drug resistance (PDR). A cocktail of phages and antibiotics can also reduce surgical-site infections more effectively than phages alone. In light of these encouraging results, clinical trials and research with phages will continue in the near future to treat surgical-site infections, biofilm removal, and antibiotic-resistant wounds, all of which could be used to prescribe phages as an alternative to antibiotics.
Identifiants
pubmed: 38308075
doi: 10.1007/s15010-024-02178-0
pii: 10.1007/s15010-024-02178-0
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
385-402Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Chopra H, Islam MA, Sharun K, Emran TB, Al-Tawfiq JA, Dhama K. Recent advances in the treatment of biofilms induced surgical site infections. Int J Surg. 2023;109:65–7.
pubmed: 36799798
pmcid: 10389243
doi: 10.1097/JS9.0000000000000036
Hrynyshyn A, Simões M, Borges A. Biofilms in surgical site infections: recent advances and novel prevention and eradication strategies. Antibiotics. 2022;11:69.
pubmed: 35052946
pmcid: 8773207
doi: 10.3390/antibiotics11010069
Mora-Guzman I, Rubio-Perez I, González RM, Garcia DD, Martin-Perez E. Surgical Site Infection by Carbapenemase-producing Enterobacteriaceae: a challenge for today’s surgeons. Cirugía Española (English Edition). 2020;98:342–9.
doi: 10.1016/j.cireng.2020.06.004
Menz BD, Charani E, Gordon DL, Leather AJ, Moonesinghe SR, Phillips CJ. Surgical antibiotic prophylaxis in an era of antibiotic resistance: common resistant bacteria and wider considerations for practice. Infection and Drug Resistance. 2021:5235–52.
Cesta N, Pini M, Mulas T, Materazzi A, Ippolito E, Wagemans J, et al., editors. Application of phage therapy in a case of a chronic hip-prosthetic joint infection due to Pseudomonas aeruginosa: an Italian real-life experience and in vitro analysis. Open Forum Infectious Diseases; 2023: Oxford University Press US.
Santamaría-Corral G, Senhaji-Kacha A, Broncano-Lavado A, Esteban J, García-Quintanilla M. Bacteriophage-antibiotic combination therapy against pseudomonas aeruginosa. Antibiotics. 2023;12:1089.
pubmed: 37508185
pmcid: 10376841
doi: 10.3390/antibiotics12071089
Metsemakers W-J, Onsea J, Moriarty TF, Pruidze N, Nadareishvili L, Dadiani M, Kutateladze M. Bacteriophage therapy for human musculoskeletal and skin/soft tissue infections. Clin Microbiol Infect. 2023.
Taati Moghadam M, Amirmozafari N, Shariati A, Hallajzadeh M, Mirkalantari S, Khoshbayan A, Masjedian Jazi F. How phages overcome the challenges of drug resistant bacteria in clinical infections. Infect Drug Resistance. 2020:45–61.
Mousavi SM, Babakhani S, Moradi L, Karami S, Shahbandeh M, Mirshekar M, et al. Bacteriophage as a novel therapeutic weapon for killing colistin-resistant multi-drug-resistant and extensively drug-resistant gram-negative bacteria. Curr Microbiol. 2021:1–14.
Moghadam MT, Chegini Z, Norouzi A, Dousari AS, Shariati A. Three-decade failure to the eradication of refractory Helicobacter pylori infection and recent efforts to eradicate the infection. Curr Pharm Biotechnol. 2021;22:945–59.
pubmed: 32767919
doi: 10.2174/1389201021666200807110849
Centers for Disease Control and Prevention (CDC); National Healthcare Safety Network (NHSN). https://www.cdc.gov/nhsn/psc/ssi/index.html . Accessed on 9 Sept 2021. 2021.
Weiss AJE, A.; Andrews, R.M. Characteristics of Operating Room Procedures in U.S. Hospitals, 2011; Statistical Brief, No. 170; Agency for Healthcare Research and Quality: Rockville, MD, USA, 2014. https://www.hcup-us.ahrq.gov/reports/statbriefs/sb170-Operating-Room-Procedures-United-States-2011.pdf . Accessed on 9 Sept 2021. 2021.
McDermott KW, Freeman WJ, Elixhauser A. Overview of operating room procedures during inpatient stays in US hospitals, 2014: statistical brief# 233. 2018.
European Centre for Disease Prevention and Control. Healthcare-Associated Infections: Surgical Site Infections; Annual Epidemiological Report for 2017; European Centre for Disease Prevention and Control: Stockholm, Sweden, 2019. Available online: https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2017-SSI.pdf . 2017.
Kolasiński W. Surgical site infections–review of current knowledge, methods of prevention. Polish J Surg. 2019;91:41–7.
Krezalek MA, Hyoju S, Zaborin A, Okafor E, Chandrasekar L, Bindokas V, et al. Can methicillin-resistant Staphylococcus aureus silently travel from the gut to the wound and cause postoperative infection? Modeling the “Trojan Horse Hypothesis.” Ann Surg. 2018;267:749–58.
pubmed: 28187042
doi: 10.1097/SLA.0000000000002173
Garvin KL, Miller RE, Gilbert TM, White AM, Lyden ER. Late reinfection may recur more than 5 years after reimplantation of THA and TKA: analysis of pathogen factors. Clin Orthop Relat Res. 2018;476:345.
pubmed: 29529667
pmcid: 6259703
doi: 10.1007/s11999.0000000000000050
Nobuhara H, Yanamoto S, Funahara M, Matsugu Y, Hayashida S, Soutome S, et al. Effect of perioperative oral management on the prevention of surgical site infection after colorectal cancer surgery: A multicenter retrospective analysis of 698 patients via analysis of covariance using propensity score. Medicine. 2018;97(40).
Robson MC. Wound infection: a failure of wound healing caused by an imbalance of bacteria. Surg Clin North Am. 1997;77:637–50.
pubmed: 9194884
doi: 10.1016/S0039-6109(05)70572-7
Cochran AR, Ong KL, Lau E, Mont MA, Malkani AL. Risk of reinfection after treatment of infected total knee arthroplasty. J Arthroplasty. 2016;31:156–61.
pubmed: 27113946
doi: 10.1016/j.arth.2016.03.028
Sartelli M, C. Hardcastle T, Catena F, Chichom-Mefire A, Coccolini F, Dhingra S, et al. Antibiotic use in low and middle-income countries and the challenges of antimicrobial resistance in surgery. Antibiotics. 2020;9(8):497.
Hope D, Ampaire L, Oyet C, Muwanguzi E, Twizerimana H, Apecu RO. Antimicrobial resistance in pathogenic aerobic bacteria causing surgical site infections in Mbarara regional referral hospital. Southwestern Uganda Sci Rep. 2019;9:1–10.
Adrien HM, Alexandre AS, Romaric TS, Fanny H-a, Holden FO, Bio TS, et al. Risk factors of surgical site infection at the regional and teaching hospital center of borgou (BENIN). Int J Clin Biomed Res. 2017:1–4.
Iskandar K, Sartelli M, Tabbal M, Ansaloni L, Baiocchi GL, Catena F, et al. Highlighting the gaps in quantifying the economic burden of surgical site infections associated with antimicrobial-resistant bacteria. World J Emergency Surg. 2019;14:1–14.
doi: 10.1186/s13017-019-0266-x
Labricciosa FM, Sartelli M, Correia S, Abbo LM, Severo M, Ansaloni L, et al. Emergency surgeons’ perceptions and attitudes towards antibiotic prescribing and resistance: a worldwide cross-sectional survey. World J Emergency Surg. 2018;13:1–9.
doi: 10.1186/s13017-018-0190-5
de Kraker ME, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050? PLoS Med. 2016;13: e1002184.
pubmed: 27898664
pmcid: 5127510
doi: 10.1371/journal.pmed.1002184
Fanny MA, Holden FO, Bio T-S, Robert A, Felix AS, Yves DA, Delphin MK. Epidemiological aspects of surgical site infections in an income country: the case of regional hospital centre, Borgou (Benin). Health Sci. 2017;6:29–33.
Foschi D, Yakushkina Ao, Cammarata F, Lamperti G, Colombo F, Rimoldi S, et al. Surgical site infections caused by multi-drug resistant organisms: a case–control study in general surgery. Updates Surg. 2022;74(5):1763–71.
Badia JM, Casey AL, Rubio-Pérez I, Crosby C, Arroyo-García N, Balibrea JM. A survey to identify the breach between evidence and practice in the prevention of surgical infection: Time to take action. Int J Surg. 2018;54:290–7.
pubmed: 29704562
doi: 10.1016/j.ijsu.2018.04.038
Sartelli M, Kluger Y, Ansaloni L, Coccolini F, Baiocchi GL, Hardcastle TC, et al. Knowledge, awareness, and attitude towards infection prevention and management among surgeons: identifying the surgeon champion. World J Emergency Surg. 2018;13:1–6.
doi: 10.1186/s13017-018-0198-x
NIH Guide: Research on Microbial Biofilms. Available online: https://grants.nih.gov/grants/guide/pa-files/pa-03-047.html . Accessed on 30 Oct 2021.
Moghadam MT, Chegini Z, Khoshbayan A, Farahani I, Shariati A. Helicobacter pylori biofilm and new strategies to combat it. Curr Mol Med. 2021;21:549–61.
pubmed: 33272177
Wolcott R, Cutting KF, Dowd S. Surgical site infections: biofilms, dehiscence and delayed healing. Wounds UK. 2008;4:108–13.
Verderosa AD, Totsika M, Fairfull-Smith KE. Bacterial biofilm eradication agents: a current review. Front Chem. 2019;7:824.
pubmed: 31850313
pmcid: 6893625
doi: 10.3389/fchem.2019.00824
Edmiston CE, McBain A, Kiernan M, Leaper D. A narrative review of microbial biofilm in postoperative surgical site infections: clinical presentation and treatment. J Wound Care. 2016;25:693–702.
pubmed: 27974013
doi: 10.12968/jowc.2016.25.12.693
Dhar Y, Han Y. Current developments in biofilm treatments: wound and implant infections. Eng Regeneration. 2020;1:64–75.
doi: 10.1016/j.engreg.2020.07.003
Darvishi S, Tavakoli S, Kharaziha M, Girault HH, Kaminski CF, Mela I. Advances in the sensing and treatment of wound biofilms. Angew Chem Int Ed. 2022;61: e202112218.
doi: 10.1002/anie.202112218
Wu H, Moser C, Wang H-Z, Høiby N, Song Z-J. Strategies for combating bacterial biofilm infections. Int J Oral Sci. 2015;7:1–7.
pubmed: 25504208
doi: 10.1038/ijos.2014.65
Miller KE, Hontanilla B, Cabello A, Marre D, Armendariz L, Leiva J. The effect of late infection and antibiotic treatment on capsular contracture in silicone breast implants: a rat model. J Plast Reconstr Aesthet Surg. 2016;69:70–6.
pubmed: 26422653
doi: 10.1016/j.bjps.2015.08.027
Koo H, Allan RN, Howlin RP, Stoodley P, Hall-Stoodley L. Targeting microbial biofilms: current and prospective therapeutic strategies. Nat Rev Microbiol. 2017;15:740–55.
pubmed: 28944770
pmcid: 5685531
doi: 10.1038/nrmicro.2017.99
Ribeiro JR. Opportunities and regulatory challenges of phage therapy 2023.
Kaur R, Sethi N. Phage therapy as an alternative treatment in the fight against AMR: Real-world problems and possible futures. Emerging modalities in mitigation of antimicrobial resistance: Springer; 2022. 357–74.
Jeschke P, Starikov EB. Agricultural Biocatalysis: Biological and Chemical Applications: CRC Press; 2022.
Wallenborn JT, Vonaesch P. Intestinal microbiota research from a global perspective. Gastroenterol Report. 2022; 10:goac010.
Jamil T, Mehmood A, Farhan M, Kalim F, Hadi F, Younas K, et al. Bacteriophage therapy: effective antibiotic replacer against emerging ghost of antimicrobial resistant bacteria. One Health Triad, Unique Scientific Publishers, Faisalabad, Pakistan. 2023;1:158–67.
Ioannou P, Baliou S, Samonis G. Bacteriophages in infectious diseases and beyond—a narrative review. Antibiotics. 2023;12(6):1012.
pubmed: 37370331
pmcid: 10295561
doi: 10.3390/antibiotics12061012
Sharma N, Chhillar AK, Dahiya S, Punia A, Choudhary P, Gulia P, et al. Chemotherapeutic Strategies for Combating Staphylococcus aureus Infections. Mini Rev Med Chem. 2022;22(1):26–42.
pubmed: 33797362
doi: 10.2174/1389557521666210402150325
Khalid A, Lin RC, Iredell JR. A phage therapy guide for clinicians and basic scientists: background and highlighting applications for developing countries. Front Microbiol. 2021;11: 599906.
pubmed: 33643225
pmcid: 7904893
doi: 10.3389/fmicb.2020.599906
Royer S, Morais AP, da Fonseca Batistão DW. Phage therapy as strategy to face post-antibiotic era: a guide to beginners and experts. Arch Microbiol. 2021;203:1271–9.
pubmed: 33474609
doi: 10.1007/s00203-020-02167-5
Caflisch KM, Suh GA, Patel R. Biological challenges of phage therapy and proposed solutions: a literature review. Expert Rev Anti Infect Ther. 2019;17:1011–41.
pubmed: 31735090
pmcid: 6919273
doi: 10.1080/14787210.2019.1694905
Liang S, Qi Y, Yu H, Sun W, Raza SHA, Alkhorayef N, et al. bacteriophage therapy as an application for bacterial infection in China. Antibiotics. 2023;12:417.
pubmed: 36830327
pmcid: 9952293
doi: 10.3390/antibiotics12020417
Letarov A, Kulikov E. Adsorption of bacteriophages on bacterial cells. Biochem Mosc. 2017;82:1632–58.
doi: 10.1134/S0006297917130053
Dion MB, Oechslin F, Moineau S. Phage diversity, genomics and phylogeny. Nat Rev Microbiol. 2020;18:125–38.
pubmed: 32015529
doi: 10.1038/s41579-019-0311-5
Ackermann H-W. Phage classification and characterization. Bacteriophages: Methods and protocols, volume 1: Isolation, characterization, and interactions. 2009:127–40.
Tolstoy I, Kropinski AM, Brister JR. Bacteriophage taxonomy: an evolving discipline. Bacteriophage Therapy: From Lab to Clinical Practice. 2018:57–71.
Hatfull GF, Hendrix RW. Bacteriophages and their genomes. Curr Opin Virol. 2011;1:298–303.
pubmed: 22034588
pmcid: 3199584
doi: 10.1016/j.coviro.2011.06.009
Hitchcock NM, Devequi Gomes Nunes D, Shiach J, Valeria Saraiva Hodel K, Dantas Viana Barbosa J, Alencar Pereira Rodrigues L, et al. Current Clinical Landscape and Global Potential of Bacteriophage Therapy. Viruses. 2023;15:1020.
GenBank, Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information. Available online: https://www.ncbi.nlm.nih.gov/nuccore . Accessed on 12 Apr 2023.
SEA-PHAGES HHMI Science Education Alliance-Phage Hunters Advancing Genomics and Evolutionary Science Program. https://seaphages.org . Accessed on 9 Feb 2023.
Mavrich TN, Hatfull GF. Bacteriophage evolution differs by host, lifestyle and genome. Nat Microbiol. 2017;2:1–9.
doi: 10.1038/nmicrobiol.2017.112
Dunstan RA, Bamert RS, Belousoff MJ, Short FL, Barlow CK, Pickard DJ, et al. Mechanistic insights into the capsule-targeting depolymerase from a Klebsiella pneumoniae bacteriophage. Microbiol Spectrum. 2021;9:e01023-e1121.
doi: 10.1128/Spectrum.01023-21
Stone E, Campbell K, Grant I, McAuliffe O. Understanding and exploiting phage–host interactions. Viruses. 2019;11:567.
pubmed: 31216787
pmcid: 6630733
doi: 10.3390/v11060567
Dunne M, Hupfeld M, Klumpp J, Loessner MJ. Molecular basis of bacterial host interactions by Gram-positive targeting bacteriophages. Viruses. 2018;10:397.
pubmed: 30060549
pmcid: 6115969
doi: 10.3390/v10080397
Kortright KE, Chan BK, Koff JL, Turner PE. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe. 2019;25:219–32.
pubmed: 30763536
doi: 10.1016/j.chom.2019.01.014
Pfeifer E, Bonnin RA, Rocha EP. Phage-Plasmids spread antibiotic resistance genes through infection and lysogenic conversion. MBio. 2022;13:e01851-e1922.
pubmed: 36154183
pmcid: 9600943
doi: 10.1128/mbio.01851-22
Principi N, Silvestri E, Esposito S. Advantages and limitations of bacteriophages for the treatment of bacterial infections. Front Pharmacol. 2019;10:513.
pubmed: 31139086
pmcid: 6517696
doi: 10.3389/fphar.2019.00513
Lerminiaux NA, Cameron AD. Horizontal transfer of antibiotic resistance genes in clinical environments. Can J Microbiol. 2019;65:34–44.
pubmed: 30248271
doi: 10.1139/cjm-2018-0275
Riedel S, Hobden J, Miller S, Morse S, Mietzner T, Detrick B, et al. Microbial Genetics. Jawetz, Melnick, & Adelberg’s Medical Microbiology; McGraw Hill: New York, NY, USA. 2019.
Żbikowska K, Michalczuk M, Dolka B. The use of bacteriophages in the poultry industry. Animals. 2020;10:872.
pubmed: 32443410
pmcid: 7278383
doi: 10.3390/ani10050872
Ledsgaard L, Kilstrup M, Karatt-Vellatt A, McCafferty J, Laustsen AH. Basics of antibody phage display technology. Toxins. 2018;10:236.
pubmed: 29890762
pmcid: 6024766
doi: 10.3390/toxins10060236
Boeckaerts D, Stock M, De Baets B, Briers Y. Identification of phage receptor-binding protein sequences with hidden markov models and an extreme gradient boosting classifier. Viruses. 2022;14:1329.
pubmed: 35746800
pmcid: 9230537
doi: 10.3390/v14061329
Boeckaerts D, Stock M, Criel B, Gerstmans H, De Baets B, Briers Y. Predicting bacteriophage hosts based on sequences of annotated receptor-binding proteins. Sci Rep. 2021;11:1467.
pubmed: 33446856
pmcid: 7809048
doi: 10.1038/s41598-021-81063-4
Floccari VA, Dragoš A. Host control by SPβ phage regulatory switch as potential manipulation strategy. Curr Opin Microbiol. 2023;71: 102260.
pubmed: 36580707
doi: 10.1016/j.mib.2022.102260
White K, Yu J-H, Eraclio G, Dal Bello F, Nauta A, Mahony J, van Sinderen D. Bacteriophage-host interactions as a platform to establish the role of phages in modulating the microbial composition of fermented foods. Microbiome Res Reports. 2022:1–19.
de Jonge PA, Nobrega FL, Brouns SJ, Dutilh BE. Molecular and evolutionary determinants of bacteriophage host range. Trends Microbiol. 2019;27:51–63.
pubmed: 30181062
doi: 10.1016/j.tim.2018.08.006
Melo LD, Oliveira H, Pires DP, Dabrowska K, Azeredo J. Phage therapy efficacy: a review of the last 10 years of preclinical studies. Crit Rev Microbiol. 2020;46:78–99.
pubmed: 32091280
doi: 10.1080/1040841X.2020.1729695
El Haddad L, Harb CP, Gebara MA, Stibich MA, Chemaly RF. A systematic and critical review of bacteriophage therapy against multidrug-resistant ESKAPE organisms in humans. Clin Infect Dis. 2019;69:167–78.
pubmed: 30395179
doi: 10.1093/cid/ciy947
Nadareishvili L, Hoyle N, Nakaidze N, Nizharadze D, Kutateladze M, Balarjishvili N, et al. Bacteriophage therapy as a potential management option for surgical wound infections. Phage. 2020;1:158–65.
pubmed: 36147826
pmcid: 9041461
doi: 10.1089/phage.2020.0010
Hassannia M, Naderifar M, Salamy S, Akbarizadeh MR, Mohebi S, Moghadam MT. Engineered phage enzymes against drug-resistant pathogens: a review on advances and applications. Bioprocess and Biosystems Engineering. 2023:1–12.
Boroujeni MB, Mohebi S, Malekian A, Shahraeini SS, Gharagheizi Z, Shahkolahi S, et al. The therapeutic effect of engineered phage, derived protein and enzymes against superbug bacteria. Biotechnology and Bioengineering. 2023.
Regeimbal JM, Jacobs AC, Corey BW, Henry MS, Thompson MG, Pavlicek RL, et al. Personalized therapeutic cocktail of wild environmental phages rescues mice from Acinetobacter baumannii wound infections. Antimicrob Agents Chemother. 2016;60:5806–16.
pubmed: 27431214
pmcid: 5038255
doi: 10.1128/AAC.02877-15
Morris JL, Letson HL, Elliott L, Grant AL, Wilkinson M, Hazratwala K, McEwen P. Evaluation of bacteriophage as an adjunct therapy for treatment of peri-prosthetic joint infection caused by Staphylococcus aureus. PLoS ONE. 2019;14: e0226574.
pubmed: 31877146
pmcid: 6932802
doi: 10.1371/journal.pone.0226574
Leitner L, Ujmajuridze A, Chanishvili N, Goderdzishvili M, Chkonia I, Rigvava S, et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infect Dis. 2021;21:427–36.
pubmed: 32949500
doi: 10.1016/S1473-3099(20)30330-3
Rubalskii E, Ruemke S, Salmoukas C, Boyle EC, Warnecke G, Tudorache I, et al. Bacteriophage therapy for critical infections related to cardiothoracic surgery. Antibiotics. 2020;9:232.
pubmed: 32380707
pmcid: 7277081
doi: 10.3390/antibiotics9050232
Gupta P, Singh HS, Shukla VK, Nath G, Bhartiya SK. Bacteriophage therapy of chronic nonhealing wound: clinical study. Int J Low Extrem Wounds. 2019;18:171–5.
pubmed: 31081402
doi: 10.1177/1534734619835115
Rostkowska OM, Międzybrodzki R, Miszewska‐Szyszkowska D, Górski A, Durlik M. Treatment of recurrent urinary tract infections in a 60‐year‐old kidney transplant recipient. The use of phage therapy. Transpl Infect Dis. 2021;23:e13391.
Tkhilaishvili T, Winkler T, Müller M, Perka C, Trampuz A. Bacteriophages as adjuvant to antibiotics for the treatment of periprosthetic joint infection caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;64:e00924-e1019.
pubmed: 31527029
pmcid: 7187616
doi: 10.1128/AAC.00924-19
Chan BK, Turner PE, Kim S, Mojibian HR, Elefteriades JA, Narayan D. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Publ Health. 2018;2018:60–6.
doi: 10.1093/emph/eoy005
Fish R, Kutter E, Wheat G, Blasdel B, Kutateladze M, Kuhl S. Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. J Wound Care. 2016;25:S27–33.
doi: 10.12968/jowc.2016.25.7.S27
Ferry T, Kolenda C, Batailler C, Gustave C-A, Lustig S, Malatray M, et al. Phage therapy as adjuvant to conservative surgery and antibiotics to salvage patients with relapsing S. aureus prosthetic knee infection. Front Med. 2020;7:570572.
Racenis K, Rezevska D, Madelane M, Lavrinovics E, Djebara S, Petersons A, Kroica J. Use of phage cocktail BFC 1.10 in combination with ceftazidime-avibactam in the treatment of multidrug-resistant Pseudomonas aeruginosa femur osteomyelitis—a case report. Front Med. 2022;9
Jault P, Leclerc T, Jennes S, Pirnay JP, Que Y-A, Resch G, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 2019;19:35–45.
pubmed: 30292481
doi: 10.1016/S1473-3099(18)30482-1
Aslam S, Lampley E, Wooten D, Karris M, Benson C, Strathdee S, Schooley RT, editors. Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States. Open forum infectious diseases; 2020: Oxford University Press US.
Duplessis C, Biswas B, Hanisch B, Perkins M, Henry M, Quinones J, et al. Refractory Pseudomonas bacteremia in a 2-year-old sterilized by bacteriophage therapy. J Pediatric Infect Dis Soc. 2018;7:253–6.
pubmed: 28992111
doi: 10.1093/jpids/pix056
Leitner L, Sybesma W, Chanishvili N, Goderdzishvili M, Chkhotua A, Ujmajuridze A, et al. Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial. BMC Urol. 2017;17:1–6.
doi: 10.1186/s12894-017-0283-6
Aslam S, Pretorius V, Lehman SM, Morales S, Schooley RT. Novel bacteriophage therapy for treatment of left ventricular assist device infection. J Heart Lung Transpl. 2019;38:475–6.
doi: 10.1016/j.healun.2019.01.001
Eskenazi A, Lood C, Wubbolts J, Hites M, Balarjishvili N, Leshkasheli L, et al. Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae. Nat Commun. 2022;13:302.
pubmed: 35042848
pmcid: 8766457
doi: 10.1038/s41467-021-27656-z
Ferry T, Kolenda C, Laurent F, Leboucher G, Merabischvilli M, Djebara S, et al. Personalized bacteriophage therapy to treat pandrug-resistant spinal Pseudomonas aeruginosa infection. Nat Commun. 2022;13:4239.
pubmed: 35869081
pmcid: 9306240
doi: 10.1038/s41467-022-31837-9
Van Nieuwenhuyse B, Van der Linden D, Chatzis O, Lood C, Wagemans J, Lavigne R, et al. Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler. Nat Commun. 2022;13:5725.
pubmed: 36175406
pmcid: 9523064
doi: 10.1038/s41467-022-33294-w
Onsea J, Soentjens P, Djebara S, Merabishvili M, Depypere M, Spriet I, et al. Bacteriophage application for difficult-to-treat musculoskeletal infections: development of a standardized multidisciplinary treatment protocol. Viruses. 2019;11:891.
pubmed: 31548497
pmcid: 6832313
doi: 10.3390/v11100891
Lebeaux D, Merabishvili M, Caudron E, Lannoy D, Van Simaey L, Duyvejonck H, et al. A case of phage therapy against pandrug-resistant Achromobacter xylosoxidans in a 12-year-old lung-transplanted cystic fibrosis patient. Viruses. 2021;13:60.
pubmed: 33466377
pmcid: 7824836
doi: 10.3390/v13010060
Van Nieuwenhuyse B, Galant C, Brichard B, Docquier P-L, Djebara S, Pirnay J-P, et al. A case of in situ phage therapy against Staphylococcus aureus in a bone allograft polymicrobial biofilm infection: Outcomes and phage-antibiotic interactions. Viruses. 2021;13:1898.
pubmed: 34696328
pmcid: 8539586
doi: 10.3390/v13101898
Fedorov E, Samokhin A, Kozlova Y, Kretien S, Sheraliev T, Morozova V, et al. Short-term outcomes of phage-antibiotic combination treatment in adult patients with periprosthetic hip joint infection. Viruses. 2023;15:499.
pubmed: 36851713
pmcid: 9964274
doi: 10.3390/v15020499
Doub JB, Chan B, Johnson AJ. Salphage: Salvage bacteriophage therapy for a chronic Enterococcus faecalis prosthetic joint infection. IDCases. 2023;33: e01854.
pubmed: 37577050
pmcid: 10413068
doi: 10.1016/j.idcr.2023.e01854